Evidence map›Paper›PMID 42749262›Full record

ArticleThe Journal of biological chemistry2026

A sensitive interactome-based approach to characterize drug activity in living human cells.

Cindy Kundlacz, Christelle Forcet, Nawal Hajj Sleiman, Samantha Vonau, Frédéric Marmigère, Benjamin Gillet, Sandrine Hughes, Laurent Gilquin, Hélène Duplus, Agnès Dumont and 6 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cindy KundlaczInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France.
Christelle ForcetInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France.
Nawal Hajj SleimanInstitut Pasteur, Université Paris-Cité, CNRS-UMR 3528, Ingénierie des Anticorps, 25 Rue du Dr Roux, 75015 Paris, France. Institut Pasteur, Université Paris-Cité, UMR / INSERM - U1347, Unité de Parasitologie Moléculaire et Signalisation, Paris, France.
Samantha VonauInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France.
Frédéric MarmigèreInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France.
Benjamin GilletInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France.
Sandrine HughesInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France.
Laurent GilquinInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France.
Hélène DuplusLaboratoire de Biologie et Modélisation de la Cellule (LBMC), UMR5239, École Normale Supérieure de Lyon (ENSL), CNRS, Université de Lyon, Lyon, France.
Agnès DumontLaboratoire de Biologie et Modélisation de la Cellule (LBMC), UMR5239, École Normale Supérieure de Lyon (ENSL), CNRS, Université de Lyon, Lyon, France.
Gaël YvertLaboratoire de Biologie et Modélisation de la Cellule (LBMC), UMR5239, École Normale Supérieure de Lyon (ENSL), CNRS, Université de Lyon, Lyon, France.
Françoise BleicherInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France.
Arnaud GautierSorbonne Université, Ecole Normale Supérieure, Université PSL, CNRS, Laboratoire des Biomolécules, LBM, Paris, France.
Isabelle CosteUniversité Claude Bernard Lyon1, INSERM U1052-CNRS UMR5286, Lyon Cancer Research Center, Centre Léon Bérard, Lyon, France.
Toufic RennoUniversité Claude Bernard Lyon1, INSERM U1052-CNRS UMR5286, Lyon Cancer Research Center, Centre Léon Bérard, Lyon, France.
Samir MerabetInstitut de Génomique Fonctionnelle de Lyon (IGFL), UMR5242, École Normale Supérieure de Lyon (ENSL), CNRS, Université Lyon-I, Lyon, France. Electronic address: samir.merabet@ens-lyon.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abnormal protein-protein interactions (PPIs) involving signaling proteins contribute to numerous human diseases. Targeting such aberrant PPIs with selective inhibitory molecules is a promising therapeutic strategy, yet assessing how many PPIs are affected by a candidate drug, and whether inhibition occurs before or after complex assembly, remains technically challenging. Here, we present a live-cell methodology that captures drug-sensitive PPIs by integrating drug-induced cellular responses with interaction mapping. As a proof of concept, we identify extracellular signal-regulated kinase 1 PPIs that are selectively altered by a novel chemical molecule exhibiting antitumor efficacy. We further apply complementary real-time imaging tools to visualize the dissociation of preassembled extracellular signal-regulated kinase 1-cofactor complexes in living cells. Our approach provides a generalizable framework for decoding drug activity on PPIs for virtually any protein target, enabling more precise and physiologically relevant evaluation of therapeutic mechanisms.

Indexed as

BiFCcell-PCAEI52MAPKprotein–protein interactionsplitFAST2U0126

Identifiers

PMID42749262
PMCPMC13678014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.